OCM
AXSM icon

Occam Crest Management’s Axsome Therapeutics AXSM Stock Holding History

Occam Crest Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78M Sell
29,800
-4,814
-14% -$1.04M 3.52% 10
2026
Q1 		$5.85M Sell
34,614
-386
-1% -$66.7K 3.55% 10
2025
Q4 		$6.39M Buy
35,000
+2,000
+6% +$279K 4.44% 9
2025
Q3 		$4.01M Buy
+33,000
New +$3.72M 2.44% 13

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Occam Crest Management's AXSM Position: Q2 2026 in Review

Occam Crest Management reduced its Axsome Therapeutics (AXSM) stake by 14% in Q2 2026, selling an estimated $1.04M and leaving 29,800 shares worth $6.78M. The position accounts for 3.52% of the portfolio, ranked #10.

Occam Crest Management first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Occam Crest Management held 29,800 shares of Axsome Therapeutics worth $6.78M as of Q2 2026.
  • Occam Crest Management sold 4,814 Axsome Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Axsome Therapeutics made up 3.52% of Occam Crest Management's portfolio in Q2 2026, its #10 holding.
  • Occam Crest Management first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Occam Crest Management's 13F filing for Q2 2026, filed 14 Aug 2026.